Viral hepatitis

This phase 2 trial is testing whether a combination of two experimental drugs, BRII-835 and BRII-179, can clear the hepatitis B virus from the body in adults with chronic infection. Participants will receive the drug combination and then be monitored to see if they can safely sto…

This study tests whether 12 weeks of a three-drug antiviral combination works as well as 24 weeks for curing hepatitis C in people with chronic liver disease. Researchers will enroll 192 patients who have not been treated before and randomly assign them to either the shorter or l…

This study tested whether offering hepatitis C (HCV) treatment right at methadone clinics helps more people get cured compared to sending them to outside specialists. Over 600 adults on opioid addiction therapy took part across 13 clinics in Ukraine. Some clinics provided simplif…

This study tested a combination of four drugs (asunaprevir, daclatasvir, ribavirin, and pegylated interferon) in 60 adults with hepatitis C genotype 4 who had not responded to standard treatment. The goal was to see if this stronger therapy could clear the virus completely, with …

This study tests a hexavalent vaccine that protects against six diseases, including polio, but uses a lower dose of the inactivated polio vaccine (IPV). The goal is to see if this reduced-dose version works as well as the standard full-dose vaccine in infants. Around 1,500 health…

This early-stage trial tested a new two-part vaccine designed to treat chronic hepatitis B. It involved 26 healthy adults to check safety and immune response. The vaccine uses a protein first shot followed by a booster to teach the immune system to attack the virus.

This study tested whether a double-dose hepatitis B vaccine (40 micrograms) works better than the standard dose (20 micrograms) in people with HIV who did not respond to earlier hepatitis B shots. The goal was to see if the stronger dose could help their immune system produce eno…

This study tested three different ways of giving the hepatitis B vaccine to 437 people with HIV whose CD4 counts were above 200. The goal was to see which schedule—standard dose, double dose, or skin injections—works best to protect them from hepatitis B, a virus that can cause s…

This completed study checked the safety of the Hexaxim vaccine in 713 infants aged 2 months and older in South Korea. Researchers tracked side effects like injection site reactions, fever, and crying after routine vaccination. The goal was to confirm the vaccine's safety in every…

This study looked at whether giving young children 2 doses of the hepatitis B vaccine works as well as the usual 3 doses. Over 400 children aged 2 to 18 months took part. Researchers measured blood antibody levels to see if fewer shots still provide strong protection against the …

This early-stage study tested a new hepatitis B vaccine that includes an experimental booster called AS37. The goal was to see if the vaccine is safe and how well it triggers the immune system. 122 healthy adults aged 18-45 received two doses one month apart. Researchers monitore…

This study tested whether giving a booster polio vaccine (sIPV) at the same time as MMR and hepatitis A vaccines is safe and works well in toddlers. About 889 healthy children aged 18 to 22 months who had already received their first polio and MMR shots took part. Researchers che…

This study tested a new combination vaccine called Shan6™, which protects against six diseases (diphtheria, tetanus, whooping cough, hepatitis B, Hib, and polio) in healthy infants and toddlers in Thailand. The trial involved 460 participants and compared Shan6™ to a similar 5-in…

This study tests a drug called hydronidone in 300 adults with liver scarring (fibrosis or cirrhosis) from chronic hepatitis B. Participants take the drug three times daily for 28 days to see if it is safe. The main goal is to track any side effects.

This study tests a drug called hydronidone in 200 adults with liver fibrosis caused by chronic hepatitis B or fatty liver disease. Participants take three capsules three times daily for 28 days. The main goal is to check for side effects, not to measure how well the drug works.

This study tests a drug called hydronidone in 150 adults with liver scarring caused by chronic hepatitis B. Participants take the capsules three times daily for 28 days. The main goal is to check for side effects and ensure the drug is safe. This is an early-phase trial, so it fo…

This study tests whether adults with chronic hepatitis B who have no liver scarring can safely stop taking antiviral drugs. The 140 participants have undetectable virus levels and negative HBeAg status. Researchers will monitor for viral relapse and liver problems over time.

This early-phase trial tested an experimental drug called BW-20507 in 32 people. First, healthy volunteers received a single dose to check safety. Then, people with chronic hepatitis B received multiple doses to see how the drug behaves in the body and whether it fights the virus…

This phase 2 trial is testing whether adding an experimental drug called JNJ-73763989 to standard oral antivirals can better suppress hepatitis D virus in people who are also infected with hepatitis B. About 52 adults with stable chronic co-infection will receive either the combi…

This study tests whether offering hepatitis C testing right in community pharmacies—using a simple finger-prick device—helps more people on opioid therapy get diagnosed and cured compared to the usual approach of referring them to a clinic. Participants are adults on stable metha…

This study tests a care model where hospitalized adults with opioid use disorder and a serious infection receive long-acting injectable buprenorphine from their infectious disease doctors, alongside infection treatment. The goal is to keep patients on effective medication for opi…

This Phase 3 study tests bepirovirsen, an experimental drug, in 857 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if bepirovirsen can suppress the virus enough to allow patients to stop all hepatitis B treatments and remain viru…

This Phase 3 trial tests a drug called bepirovirsen in nearly 1,000 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if bepirovirsen can suppress the virus enough that participants can safely stop all hepatitis B medications and re…

This study tests whether offering peer support, small incentives, telehealth visits, or prepaid phones helps people with hepatitis C and substance use disorders get linked to medical care. Participants are adults in Appalachia who have tested positive for hepatitis C and have a h…

This study tested two ways to offer HIV treatment, hepatitis C treatment, and substance use disorder medications to people who inject drugs. One group received a telehealth-enhanced program with on-demand services like mobile blood draws and counseling, while the other group got …

This study tests whether the immunotherapy drug durvalumab can be safely given to people with advanced liver cancer who also have an active hepatitis B infection. All participants receive an antiviral drug (entecavir) to control the hepatitis B virus. The main goal is to see if d…

This study tested whether adding Naderin (sodium nucleinate) to standard treatment could reduce complications in 75 patients with cancer, tuberculosis, or hepatitis C. The main group received Naderin plus standard therapy, while the control group received standard therapy alone. …

This study tests whether hearts from donors with hepatitis C can be safely transplanted into people without the virus. Twenty adults with end-stage heart failure on the transplant waiting list will receive these hearts and take antiviral medication to prevent infection. The goal …

This trial tests a smartphone app called Tappt that uses smart tags to help people with hepatitis C stick to their daily oral medication. Participants scan tags each time they take a dose, and the app tracks adherence. The study compares their results to historical data from simi…

This study tested whether adding prazosin, a drug usually used for high blood pressure, to standard hepatitis C treatment could reduce liver scarring. 112 adults with chronic hepatitis C (genotype 1 or 4) and severe liver fibrosis took part. Researchers measured changes in liver …

This early-stage study tested a new treatment approach for adults with chronic hepatitis B or D. Twenty participants received two medications in sequence: P1101 (a type of interferon) followed by an anti-PD1 drug. The main goal was to check safety and tolerability, while also loo…

This study tested a combination of three drugs—Grazoprevir/Elbasvir, Sofosbuvir, and Ribavirin—in 26 adults with hepatitis C genotype 1 or 4 who had not been cured by previous treatments. The goal was to see if 16 or 24 weeks of this therapy could clear the virus. The main measur…

This completed phase 4 trial tested whether adding SB Flavon (a blend of flavonoids, vitamin C, and L-arginine) to standard Tenofovir therapy can reverse advanced liver scarring (cirrhosis) and prevent liver cancer in 134 people with chronic hepatitis B. The study measured liver …

This study tested whether a new form of interferon (IFN alfa-2b XL) combined with ribavirin works better and causes fewer side effects than the standard treatment for chronic hepatitis C (genotypes 1 or 4). 84 adults who had not been treated before or had not responded to previou…

This study tested two different approaches to help people recently released from jail or prison get connected to care for HIV, hepatitis C, STIs, and opioid use disorder. Over 600 adults took part. The goal was to see which method worked better for starting and staying on treatme…

This study tested whether Mediterranean or DASH diets improve liver function in people with nonalcoholic fatty liver disease (NAFLD). 75 adults with mild to moderate liver enzyme elevations were split into three groups: one following general dietary guidelines, one on a Mediterra…

This Phase 2 trial tested an oral drug called selgantolimod in 29 adults with both chronic hepatitis B and HIV. Participants had been on stable antiviral therapy for both viruses for at least 5 years. The study aimed to see if the drug is safe and can lower hepatitis B surface an…

This study tested a combination of peginterferon alfa2a and ribavirin in 17 HIV-positive people with chronic hepatitis C who had not responded to earlier treatment. Participants received weekly injections and daily pills for 48 weeks. The main goal was to see if the virus became …

This study tests an experimental drug called AHB-137 in healthy volunteers and people with chronic hepatitis B who are already on antiviral medication. The goal is to check if the drug is safe and shows early signs of controlling the virus. About 129 participants will receive eit…

This study tested a new way to care for people who inject drugs and have hepatitis C. Along with standard hepatitis C treatment, participants were offered HIV prevention medication and buprenorphine for opioid use disorder. The goal was to see if this combined approach could cure…

This completed Phase 3 trial tested a once-daily combination of two drugs, lonafarnib and ritonavir, in 10 adults with chronic hepatitis D. The goal was to see if the regimen is safe and can lower the amount of virus in the blood over 48 weeks of treatment and 24 weeks of follow-…

This phase 2b trial tested a combination of two experimental vaccines (VTP-300) plus a low dose of the cancer drug nivolumab in 121 adults with chronic hepatitis B who were already on antiviral medication. The goal was to see if the treatment could significantly lower hepatitis B…

This study tested whether livers from donors with hepatitis C could be safely transplanted into people without hepatitis C. Five patients on the liver transplant waiting list received these livers and were then treated with an antiviral drug to prevent infection. The goal was to …

This Phase 2 study tested an experimental drug called AB-729 combined with pegylated interferon and standard antiviral pills in 43 adults with chronic hepatitis B. The goal was to see if this approach could safely lower hepatitis B surface antigen levels and allow some participan…

This study tested whether combining two experimental drugs (VIR-2218 and VIR-3434) with or without a standard immune booster (PEG-IFNα) can safely eliminate hepatitis B surface antigen in people with chronic hepatitis B. 244 adults with long-term infection who were already on ant…

This study tested an experimental drug called VIR-2218 in 84 adults with chronic hepatitis B. Some participants received VIR-2218 alone, and others got it combined with pegylated interferon. The main goals were to check safety and how well the drug works against the virus. The st…

This study tested whether irbesartan, a blood pressure medication, can slow the progression of liver scarring (fibrosis) in adults with chronic hepatitis C who cannot take or did not respond to antiviral therapy. Over two years, 166 participants took either irbesartan or a placeb…

This study tested whether offering rapid hepatitis C treatment with help from a peer mentor (someone who has been cured) works better than the usual referral to an outside clinic. 198 people who use drugs and were in an opioid treatment program took part. The goal was to see if m…

This early-stage trial tests AB-101, an oral drug that blocks a protein called PD-L1 to help the immune system fight the hepatitis B virus. The study involves 128 people, including healthy volunteers and patients with chronic hepatitis B. Researchers are primarily checking for sa…

This study tested whether interferon-free drug combinations can cure hepatitis C in 150 people who had been successfully treated for liver cancer. Participants took pills like sofosbuvir and ribavirin for 12 weeks. The main goal was to see if the virus stayed undetectable 12 week…

This study tested a combination of three drugs (pegylated interferon, ribavirin, and boceprevir) in 58 adults with genotype 1 hepatitis C and cirrhosis who were waiting for a liver transplant. The goal was to see if the treatment could clear the virus before surgery. The study me…

This study tested a more intensive hepatitis C treatment in 58 adults who have both HIV and hepatitis C (genotypes 1 or 4) and had not responded to previous therapy. Participants received higher doses of two drugs, peginterferon alfa-2a and ribavirin, for up to 18 months. The goa…

This study looked at how the HIV drug raltegravir works in people with severe liver disease who need a liver transplant. It included 14 HIV-positive adults with end-stage liver failure. Researchers checked how the drug behaves in the body and how it interacts with anti-rejection …

This study looked at whether adding vitamin D to standard hepatitis C treatment could help patients with genotype 1 or 4 who had not responded to previous therapy. 32 adults with low vitamin D levels were enrolled. The goal was to see if vitamin D could make the antiviral drugs w…

This early-stage trial tested an experimental injection called HH-006 in 36 adults with untreated chronic hepatitis B. The study aimed to check the drug's safety, how the body processes it, and whether it can lower virus levels. Participants received either HH-006 or a placebo ov…

This phase 3 trial tested whether a single injection of radioactive lipiodol (Lipiocis) into the liver artery could prevent hepatocellular carcinoma from coming back after surgery or ablation. The study enrolled 73 adults with cirrhosis and one or two liver tumors that had been s…

This study tests whether a DNA vaccine can help people with chronic hepatitis B control the virus after they stop taking standard antiviral drugs. The vaccine aims to boost the immune system to delay the virus from becoming active again. The trial involves 70 adults who have unde…

This phase 2 study tested a combination of three drugs—telaprevir, peginterferon, and ribavirin—in 70 adults with both HIV and hepatitis C who had not been helped by standard treatment before. The goal was to see if this triple therapy could clear the hepatitis C virus from the b…

This study tested an experimental drug called HH-003 in 101 adults with chronic hepatitis delta, a serious liver disease. HH-003 is an antibody that targets hepatitis B virus, which is needed for hepatitis delta to survive. Participants received either a low or high dose of HH-00…

This completed study tested a same-day approach to hepatitis C testing and treatment in community organizations in Bangkok, Thailand. It involved 200 adults who tested positive for hepatitis C antibodies. The goal was to see if offering immediate treatment with direct-acting anti…

This study tested the drug eltrombopag in 48 Chinese adults with chronic hepatitis B and a bleeding disorder called immune thrombocytopenia (low platelets). The goal was to see if taking eltrombopag for 6 to 22 weeks could safely raise platelet counts. The trial is complete, but …

This early-stage trial tested two experimental drugs, tobevibart and elebsiran, alone or with standard treatments, in 33 adults with chronic hepatitis B. The goal was to see if these combinations could safely suppress the virus and reduce hepatitis B surface antigen levels. The s…

This study tested whether a mobile care van linked to a needle exchange program could improve HIV prevention and treatment for people who inject drugs. 720 participants received services like HIV testing, treatment, and risk reduction through the van. The goal was to see if this …

This study tested a new drug called TQA3605 in 122 adults with chronic hepatitis B who still had low levels of virus despite standard treatment. Participants took either TQA3605 or a placebo alongside their usual antiviral pills for 24 weeks. The goal was to see if adding TQA3605…

This early-stage trial tested two experimental therapeutic vaccines, GS-2829 and GS-6779, in 83 healthy people and those with chronic hepatitis B. The main goal was to check safety and tolerability, while also measuring immune responses. The vaccines are designed to help the body…

This study tested a new drug called MP-424 (Telaprevir) added to the standard two-drug therapy for hepatitis C. It involved 189 adults with genotype 1 hepatitis C who had never been treated before. The goal was to see if the triple combination could clear the virus from the blood…

This phase 2 study tested MP-424 (Telaprevir) in 15 people with genotype 1b hepatitis C who had not been treated with interferon before. Participants took three 250 mg tablets every 8 hours for 24 weeks. The main goal was to see if the virus became undetectable 24 weeks after tre…

This phase 3 trial tested a drug called telaprevir (MP-424) combined with two standard hepatitis C drugs (peginterferon and ribavirin) in 10 people with genotype 2 hepatitis C who had not responded to previous treatment. The goal was to see if this combination could clear the vir…

This completed Phase 3 trial tested an experimental drug called MP-424, combined with two standard hepatitis C medications (pegylated interferon and ribavirin), in 54 adults with genotype 1 hepatitis C. Participants were either new to treatment or had relapsed after previous ther…

This study tested a triple-drug combination—telaprevir, peginterferon, and ribavirin—in 109 adults with genotype 1 hepatitis C whose infection returned after previous treatment. The goal was to see if the new regimen could clear the virus from the blood 24 weeks after treatment e…

This study tested a new drug called MP-424 (telaprevir) added to standard therapy (peginterferon and ribavirin) for people with genotype 2 hepatitis C whose infection came back after previous treatment. The goal was to see if the combination could clear the virus for good. The tr…

This study tested a new drug called MP-424 combined with two standard medicines (interferon beta and ribavirin) in 74 adults with chronic hepatitis C (genotype 1 or 2). Participants either had never been treated before or had previously received interferon-based therapy. The main…

This study tested whether higher doses of ursodeoxycholic acid (UDCA) could better lower liver enzymes in 596 adults with chronic hepatitis C. Participants received 150, 600, or 900 mg of UDCA daily for 24 weeks. The main goal was to see if the higher doses were more effective an…

This early-phase trial tested a new hepatitis C drug called telaprevir (MP-424) combined with two standard medications (peginterferon and ribavirin) in 20 people with genotype 1b hepatitis C. The main goals were to check safety and how the drug moves through the body. Researchers…

This study tested a new drug called MP-424 combined with two standard medications (peginterferon alfa-2b and ribavirin) in 32 adults with genotype 1 hepatitis C who had not responded to earlier treatment. The main goal was to see if the virus could be cleared from the blood 24 we…

This early-phase study tested MP-424 (telaprevir) in 10 patients with chronic hepatitis C genotype 1b. Participants took three 250 mg tablets every 8 hours for 12 weeks. The main goals were to check safety, how the drug moves through the body, and how it affects hepatitis C virus…

This study looked at how safe and effective a hepatitis A vaccine is for people with HIV, aged 1 to 50. About 392 participants received two vaccine doses six months apart. Researchers checked their blood for antibodies and tracked any side effects for a month after each dose. The…

This completed phase 2 study tested a two-step treatment for chronic hepatitis B. First, participants received an antisense drug (bepirovirsen) for 12 or 24 weeks, followed by a targeted immunotherapy. The goal was to see if this sequence could safely improve virus control beyond…

This study tested an experimental injection called RBD1016 in 48 adults with chronic hepatitis B who were already taking standard antiviral pills. The goal was to see if the injection could safely lower hepatitis B surface antigen (HBsAg), a marker of the virus. Participants rece…

This study tested whether adding pegylated interferon alfa-2a to standard nucleoside analogue therapy could help people with chronic hepatitis B lose the hepatitis B surface antigen (HBsAg). 119 adults with HBeAg-negative chronic hepatitis B who had been on nucleoside analogues f…

This early-stage trial tests an experimental oral drug called ALG-000184 in healthy volunteers and people with chronic hepatitis B. The main goals are to check safety, how the body processes the drug, and whether it can lower hepatitis B virus levels. Participants take the drug d…

This study tested a new combination of two antiviral pills, bemnifosbuvir and ruzasvir, taken once daily for 8 weeks in 275 adults with chronic hepatitis C. The main goal was to see if the virus was still undetectable 12 weeks after treatment ended. The trial is now complete, and…

This study tested an experimental drug called ARO-HBV in healthy volunteers and people with chronic hepatitis B. The drug uses RNA interference to try to stop the virus from multiplying. The main goal was to check safety and how the body processes the drug, not yet to prove it wo…

This early-stage trial tested a DNA vaccine in 10 adults with chronic hepatitis B who had not responded to standard treatments. The vaccine was designed to train the immune system to fight the virus. The main goal was to check safety, with a secondary goal of seeing if the vaccin…

This study tested several new drug combinations in 281 people with chronic hepatitis B who were already on standard antiviral therapy. The goal was to see if adding experimental drugs could clear a key virus marker (HBsAg) from the blood. Participants received different combinati…

This early-stage study looked at how the drug bulevirtide behaves in people with chronic hepatitis D who also have normal or impaired kidney function. Researchers measured drug levels in the blood, its effect on bile acids, and overall safety. The study enrolled 41 adults and gav…

This study tested whether offering hepatitis C treatment at the same clinic where people receive opioid therapy leads to better outcomes than referring them to a separate infectious disease clinic. About 298 people on opioid therapy with chronic hepatitis C took part. The goal wa…

This completed Phase 4 trial tested a herbal supplement called AntiCov-220 in 82 people with underlying health conditions, including HIV and cancer. The goal was to see if it could prevent and treat COVID-19 by boosting the immune system and fighting the virus. The study compared…

This study checked how well new blood tests (Access HBV assays) can detect hepatitis B infection. Researchers tested over 21,000 leftover blood samples from adults, including blood donors and hospital patients. The goal was to see if these tests are accurate compared to existing …

This study looked at whether measuring tiny molecules called microRNAs in the blood can help diagnose liver cancer (hepatocellular carcinoma) in people with hepatitis C. Researchers tested blood samples from 84 participants, including healthy people and those with hepatitis C, wi…

This study tested how well a special MRI scan called LiverMultiScan can measure liver fat, iron, and scarring. 61 adults with various liver diseases had up to 6 scans on different machines. The goal was to see if the results are consistent when repeated on the same scanner or on …

This study tested a strategy of using rapid, point-of-care diagnostic tests for sexually transmitted infections (STIs) in pregnant women attending antenatal clinics in Zimbabwe. Over 1,000 women were offered testing for chlamydia, gonorrhea, trichomoniasis, syphilis, and hepatiti…

This trial tests whether a three-dose hepatitis B vaccine can protect healthcare workers in Zambia from infection. The vaccine is given at 0, 1, and 6 months, and blood tests measure the immune response. The goal is to see if the vaccine produces protective antibodies and cellula…

This study tested whether a mobile app (GeoPassport), financial incentives, and peer mentor support could help men who have sex with men and transgender women leaving jail access HIV prevention services like PrEP and testing. 233 participants were enrolled and followed for 9 mont…

This study tested whether giving pregnant women with hepatitis B a daily pill (tenofovir) plus giving their newborns a hepatitis B vaccine at birth could safely prevent the virus from passing to the baby. The trial enrolled 317 women in the Democratic Republic of Congo and follow…

This study tested two simple methods—mechanical vibration and flick tapping—to reduce pain in 80 infants receiving their second hepatitis B vaccine. Babies were randomly assigned to one of the two techniques, and researchers measured pain scores, crying time, and vital signs. The…

This study looked at 805 blood donors who tested positive for hepatitis C virus (HCV) to learn how the virus spreads and affects health over time. Researchers collected blood samples and health information to track infection and liver disease. The goal was to better understand HC…

This early-stage trial will test a new drug called hydronidone, which is being developed for liver fibrosis caused by hepatitis B. Since patients often need to take antiviral drugs for hepatitis B, researchers want to see if hydronidone can be taken safely alongside four common a…

This study looks back at the medical records of 1,000 adults with both chronic hepatitis B and metabolic fatty liver disease. The goal is to understand how these conditions affect kidney function, especially in people on long-term antiviral therapy. Researchers will also examine …

This study tested whether people with chronic hepatitis B who had been on antiviral drugs for at least 4 years could safely stop treatment. Fifteen adults were monitored with monthly blood tests for 6 months after stopping, then every 3 months. The goal was to see if the virus st…

This study examines whether long-term use of antiviral drugs for chronic hepatitis B is linked to kidney problems in patients who also have non-alcoholic fatty liver disease. Researchers will analyze medical records from 300 patients to compare kidney function among those taking …

Hepatitis E can cause severe liver problems in people who have had an organ transplant, and may become chronic. This study screens liver and kidney transplant patients in Guadeloupe using blood tests to measure how many carry the virus. The goal is to learn whether routine screen…

This large study in Pakistan tracks 25,000 adults with hepatitis C to see how well current government-sponsored treatments work and whether the virus develops resistance. Researchers will measure cure rates, new infections, and reinfections over time. The goal is to find the best…

This study checked how many organ transplant recipients in the U.S. have antibodies to the hepatitis E virus, which can become chronic in people with weakened immune systems. Researchers enrolled 447 adults who had a liver, kidney, or small bowel transplant or were on a waiting l…

This study investigates whether a single dose of bepirovirsen, a potential treatment for hepatitis B, affects the heart's electrical activity. Healthy adults aged 18 to 55 receive either the drug or a placebo, and their heart rhythms are monitored continuously by ECG. The goal is…

This study looks at whether simple, non-invasive blood test scores can predict the risk of developing liver cancer in people with advanced liver disease who have been cured of hepatitis C. Researchers analyzed data from 571 adults treated at a single hospital over ten years. The …

This study follows adults in Zambia who have both HIV and chronic hepatitis B to track liver health over up to 10 years. Researchers aim to understand how current HIV treatments affect hepatitis B and liver damage, and to identify factors that lead to serious outcomes like liver …

This study looked at whether it's possible to create a group of people with hepatitis C in Hai Phong, Vietnam, for future research. 300 adults with active hepatitis C took part. The goal was to see how many patients could be enrolled and how much information could be collected, n…

This study looks at how certain genetic changes (mutations) in the hepatitis B virus (HBV) affect the amount of virus in the blood of people with chronic infection. Researchers analyzed blood samples from 92 patients not on antiviral treatment. They found that specific mutations …

This study followed 326 adults in Zambia with chronic hepatitis B for up to 5 years. Researchers tracked how the virus behaves, how many patients need treatment, and how many develop serious liver problems like cirrhosis or liver cancer. The goal was to better understand the dise…

This study followed 250 chronic hepatitis B patients over age 30 who had detectable virus but normal liver enzyme levels (ALT). All had never received antiviral treatment before. Researchers measured how many became virus-negative after 48 weeks of antiviral therapy, and how many…

This study looked at two faster ways to test for hepatitis C in people who recently injected drugs and visit needle exchange programs. One method uses a fingerstick test with results in about an hour, and the other uses a dried blood spot sent to a lab. The goal was to see if the…

This study looked at how many people with cirrhosis in French general hospitals were vaccinated against diseases like hepatitis, flu, and COVID-19. Researchers surveyed 742 patients to see if they were up to date on their shots. The goal was to find gaps in vaccination coverage s…

This study offered a rapid hepatitis C test to 1,500 women aged 50-74 who were already coming in for breast cancer screening in Montpellier, France. The goal was to see how many women would agree to the extra test and how many had undiagnosed hepatitis C. Women who tested positiv…

This study tested a new ultrasound technique called ARFI to measure liver stiffness in 109 people, including healthy volunteers and patients with liver conditions. The goal was to understand normal stiffness values and how they change with disease or treatment. This is an observa…

This study looked at how bacteria from the gut might travel to the liver and make liver disease worse in people with hepatitis C. Thirty adults with stable liver disease took part. Researchers used blood tests, MRI scans, and liver tissue samples to measure bacterial movement and…

This study tested 892 African and Asian immigrants for hepatitis B and C to understand how these infections raise the risk of liver cancer. Researchers also checked vaccination rates and tracked new cancer cases over time. No treatment was given; the goal was to gather informatio…

This study looked at how factors like chronic stress and depression might speed up liver damage in Korean Americans with chronic hepatitis B. Researchers followed 365 participants over time, collecting health records, hair samples, and interview data. The goal was to understand w…

This study looked at how people with chronic liver disease (like hepatitis B, C, or fatty liver) respond to COVID-19 vaccines. About 233 adults had three visits over a year to check their immune response and see if they got COVID-19. The goal was to understand if liver disease af…

This study looked at whether treating hepatitis C in people who inject drugs can prevent the virus from spreading to others. Researchers analyzed health records of about 2,800 people in NHS Tayside who were tested or treated for hepatitis C. No new treatments or procedures were g…

This study followed 450 transgender people (300 HIV-negative and 150 living with HIV) from community health centers in Thailand, Vietnam, and the Philippines for 24 months. Researchers tracked new HIV infections, mental health, and social factors like stigma and violence using su…

This study tested a digital, community-led program to help people in rural Appalachia and the Midwest reduce their risk of HIV and hepatitis C, often linked to opioid use. Over 500 adults took part, with half currently or previously using illicit substances. The program included …

This study tested new MRI and MRE techniques that let children breathe normally during scans, instead of holding their breath. The goal was to measure liver fat and stiffness more comfortably and accurately in kids with fatty liver disease. 135 children aged 6-17 took part, and t…

This completed study looked at 274 foreign-born adults in the US with chronic hepatitis B to understand why many do not get proper follow-up care. Participants completed a one-time survey about their background, immigration experience, and healthcare access. The goal is to identi…

This completed Phase 1 study looked at how the drug bulevirtide (Hepcludex) behaves in the body of people with normal liver function and those with liver impairment. Researchers measured drug levels in the blood and how quickly it is cleared. The study involved 74 participants an…

This study looked at over 5,000 adults in Zambia to find out how many have hepatitis B and how many need treatment. Researchers tested people in their homes and then did more tests on those who tested positive. The goal was to gather information, not to test a new treatment or cu…

This study looked at how many medical students have immunity against hepatitis B and varicella-zoster (chickenpox) viruses. Researchers tested 401 students to see their protection levels and vaccination rates. The goal was to understand if current immunization programs are workin…

This study tested 350 detainees in Nîmes, France for HIV, hepatitis B, and hepatitis C using rapid diagnostic tests. Many detainees come from areas where these infections are common and often don't know their status. The goal was to find out how many are infected so that care can…

This early-stage study tested the safety and how the body processes a new drug called ABI-6250 in 40 healthy adults. Participants received either the drug or a placebo, and researchers measured side effects and drug levels in the blood. The goal was to gather safety information b…

This observational study checked whether children with hepatitis C who also have thalassemia or survived childhood cancer are more likely to develop insulin resistance (a step toward diabetes). Researchers compared 90 infected children to healthy kids of the same age and gender. …

This study tested a program called CJC-TraC, where a nurse case manager helps incarcerated individuals with HIV, hepatitis C, or substance use disorder prepare for release and connect to community healthcare. The program involved up to 4 in-person or telehealth visits before rele…

This completed study looked at 217 adults with chronic hepatitis B to see how common fatty liver and fatty pancreas are in obese versus lean patients. Researchers used ultrasound and a special liver stiffness test to measure fat and scarring. The goal was to learn more about how …

This study looked at human proteins that stick to hepatitis B virus particles in blood samples from 14 infected adults. The goal was to identify these proteins and understand how they help the virus survive and spread. This is basic research, not a treatment, but it may point tow…

This completed study looked at whether COVID-19 patients treated with steroids might have a reactivation of hepatitis B virus (HBV). Researchers followed 1,793 hospitalized adults who needed oxygen and received steroids for COVID-19 pneumonia. The goal was to see how well doctors…

This study aims to identify human proteins that stick to hepatitis C virus particles in patient blood samples. By understanding which proteins the virus uses to survive and spread, researchers hope to find new targets for future treatments. Ten adults with chronic hepatitis C eac…